Products
Basiliximab Biosimilar Monoclonal Antibody (CD25) for Research
Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-049-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody |
| INN Name | Basiliximab |
| Target | IL2RA |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | 1mim:HL/3iu3:AB:CD:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 1996 |
| Year Recommended | 1997 |
| Companies | Cerimon Pharmaceuticals;Novartis |
| Conditions Approved | Renal transplant rejection;Transplant rejection |
| Conditions Active | na |
| Conditions Discontinued | Ulcerative colitis;Uveitis |
| Development Tech | na |
About target - IL2RA
1. Protein Interleukin-2 receptor subunit alpha
2. Gene IL2RA
3. Organism Homo sapiens (Human)
Function
Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.
